Semaglutide: First generic announced for 2026 in Canada Canadian company Sandoz is set to launch the very first generic semaglutide in 2026, making this costly treatment more accessible, possibly raising other issues. The most common medication mistakes in long-term careHydromorphone was the medication most commonly involved in medication incidents in long-term care, according to a recent ISMP Canada analysis. Is hormone therapy keeping postmenopausal women ‘younger’? Phenotypic and chronological ages are further apart among those using the therapy. Helping patients handle wrinkles and saggy skin as a side-effect of rapid weight loss How can they be treated or prevented? Pseudoephedrine: risk of PRES/RCVS The European Pharmacovigilance Risk Assessment Committee reviewed reported cases and post-marketing safety data to evaluate the risks of PRES and RCVS with pseudoephedrine-containing medicines. Drug News—September 2024 A review of new launches, new indications, new dosage forms and Health Canada advisories. NEW PRODUCT: Noyada Get the info you need on this new product, part of our drug news roundup for September. Which medications are most effective for treatment of acute migraine headache? Systematic review and meta-analysis compares effects of 17 oral monotherapies for acute management of migraine episodes in adults. Seven new indications for drugs doctors and pharmacists should know about Get the info you need on this on new indications for seven existing drugs, part of our drug news roundup for September. Six common natural products potentially harmful to the liver One study showed 15.6 million U.S. adults consume so-called natural products associated with hepatotoxic risks. First Previous 16 17 18 19 20 Next Last
